Pathological findings of rivaroxaban-associated hemorrhagic pericarditis

Masaki Kodaira; Hiroyuki Yamazaki; Ryota Tabei; Toshiki Kuno; Kazuhiko Shimizu; Yohei Numasawa

doi:10.1253/circj.CJ-18-0094

Pathological findings of rivaroxaban-associated hemorrhagic pericarditis

Masaki Kodaira
, Hiroyuki Yamazaki
, Ryota Tabei
, Toshiki Kuno
, Kazuhiko Shimizu
, Yohei Numasawa

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	2917-2918
Number of pages	2
Journal	Circulation Journal
Volume	82
Issue number	11
DOIs	https://doi.org/10.1253/circj.CJ-18-0094
Publication status	Published - 2018
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-18-0094

Cite this

@article{d98f45ea023a4e1899a69eedae792a61,

title = "Pathological findings of rivaroxaban-associated hemorrhagic pericarditis",

author = "Masaki Kodaira and Hiroyuki Yamazaki and Ryota Tabei and Toshiki Kuno and Kazuhiko Shimizu and Yohei Numasawa",

year = "2018",

doi = "10.1253/circj.CJ-18-0094",

language = "English",

volume = "82",

pages = "2917--2918",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "11",

}

TY - JOUR

T1 - Pathological findings of rivaroxaban-associated hemorrhagic pericarditis

AU - Kodaira, Masaki

AU - Yamazaki, Hiroyuki

AU - Tabei, Ryota

AU - Kuno, Toshiki

AU - Shimizu, Kazuhiko

AU - Numasawa, Yohei

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/pages/publications/85055579647

UR - https://www.scopus.com/pages/publications/85055579647#tab=citedBy

U2 - 10.1253/circj.CJ-18-0094

DO - 10.1253/circj.CJ-18-0094

M3 - Comment/debate

C2 - 29769458

AN - SCOPUS:85055579647

SN - 1346-9843

VL - 82

SP - 2917

EP - 2918

JO - Circulation Journal

JF - Circulation Journal

IS - 11

ER -

Pathological findings of rivaroxaban-associated hemorrhagic pericarditis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this